Winnierules schreef op 24 februari 2015 09:22:
Verwachting is dat de concurrentie positie alleen maar beter wordt aangezien Ruconest minder bijverschijnselen heeft.
De vraag van de believers..is wanneer???? goed product,maar dan eerst de eerste verkoop resultaten laten zien! Sijmen De Vries..waar wacht je..weet je wat SDV moet doen...een TV spot maken,waarbij hij zelf met zijn stafleden, dit middel gebruikt..en nog zonder bijverschijnselen...
We believe the U.S. Ruconest presence is moving into good hands with no
expected issues related to sales or clinical development. Recall that the Phase
II prophylaxis crossover study has a relatively low number of patients to be
enrolled and we therefore expect a relatively quick time to study completion
and data. With this new potential indication in HAE prophylaxis, we believe
Ruconest represents a "clear and present danger" to Shire's Cinryze and that
Ruconest could compete on cost and more importantly on potential safety
differentiation. Cinryze and other plasma based products have clear warnings
on their labels, specifically the risk for thromboembolic events as well as
infectious disease risk. Ruconest benefits from a benign safety profile, with
no thromboembolic events seen to date, compared to plasma derived Cinryze
and Berinert with an incidence of ~3.4% rate of thrombosis events. We also
believe that Ruconest will compete on pricing based on its attractive COGS.